TP53 and breast cancer: Given the fact that MDM2 and MDMX have well-characterized functions in breast cancer formation and progression (reviewed in [34]), the ERα-mediated, p53-independent upregulation of MDM2 and MDMX will likely enhance these tumor-promoting processes [42].